3,4-Difluorobenzocurcumin Inhibits Vegfc-Vegfr3-Erk Signalling to Block Developmental Lymphangiogenesis in Zebrafish
Kazuhide S Okuda, Mei Fong Ng, Nur Faizah Ruslan, Neil I Bower, Dedrick Soon Seng Song, Huijun Chen, Sungmin Baek, Philip S Crosier, Katarzyna Koltowska, Jonathan W Astin, Pei Jean Tan, Benjamin M Hogan, Vyomesh Patel
Pharmaceuticals | MDPI AG | Published : 2021
Lymphangiogenesis, the formation of new lymphatic vessels from pre-existing vasculature, plays critical roles in disease, including in cancer metastasis and chronic inflammation. Preclinical and recent clinical studies have now demonstrated therapeutic utility for several anti-lymphangiogenic agents, but optimal agents and efficacy in different settings remain to be determined. We tested the anti-lymphangiogenic property of 3,4-Difluorobenzocurcumin (CDF), which has previously been implicated as an anti-cancer agent, using zebrafish embryos and cultured vascular endothelial cells. We used transgenic zebrafish labelling the lymphatic system and found that CDF potently inhibits lymphangiogenes..View full abstract
Awarded by National Heart Foundation/NHMRC
This work was supported in part by the Terry Fox Run Kuala Lumpur grant (KO), Internal grant by the Cancer Research Malaysia (VP), and the National Heart Foundation/NHMRC Career Development Fellowship (BH, 1083811).